Literature DB >> 34545444

LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?

Roberto Cannella1,2, Federica Vernuccio3, Michela Antonucci3, Domenico Salvatore Gagliano3, Francesco Matteini3, Massimo Midiri3, Giuseppe Brancatelli3.   

Abstract

OBJECTIVES: The Liver Imaging Reporting and Data System algorithm allows category downgrade in the presence of ancillary features (AFs) favoring benignity, even in observations categorized as LR-5. This study aims to assess the role of AFs favoring benignity in LR-5 observations and their impact on category downgrade.
METHODS: This study included high-risk patients with at least one LR-5 observation imaged with gadoxetate disodium MRI. Three readers with different experience levels independently evaluated the presence of AFs favoring malignancy (not hepatocellular carcinoma (HCC) in particular and HCC in particular) and AFs favoring benignity. Category downgrade was considered possible in the presence of ≥ 1 AF favoring benignity and no AF favoring malignancy. Correlation between observations size and number of AFs was assessed using Spearman's rank correlation coefficient. Cohen's kappa (k) test was used to assess inter-reader agreement.
RESULTS: The final study cohort included 162 LR-5 (mean size: 23 ± 16 mm) in 119 patients. AFs favoring benignity were reported in 9 (5.6%), 20 (12.3%), and 10 (6.2%) LR-5 observations by reader 1, reader 2, and reader 3, respectively. Hepatobiliary phase isointensity was observed in 6 (3.7%), 2 (1.2%), and 7 (4.3%) observations, respectively. Category downgrade was considered possible in only one (0.6%) observation by reader 1 and reader 3. There was a significant correlation between observation size and number of AFs favoring malignancy (p < 0.001), not HCC in particular (p ≤ 0.010), and favoring HCC in particular (p < 0.001). Inter-reader agreement of AFs favoring benignity was poor to moderate (k range: - 0.01, 0.43).
CONCLUSIONS: AFs favoring benignity are not uncommon in LR-5 observations, but category downgrade is exceptional. KEY POINTS: • Ancillary features favoring benignity are encountered in 5.6-12.3% of observations categorized as LR-5. • Category downgrade of LR-5 observations is very rare (0.6% of observations) in the presence of AFs favoring benignity due to the high prevalence (98-99%) of ancillary features favoring malignancy in LR-5 observations. • The inter-reader agreement of ancillary features favoring benignity is poor to moderate (k range: - 0.01, 0.43) in readers with different levels of experience.
© 2021. European Society of Radiology.

Entities:  

Keywords:  Cirrhosis; Gadoxetate disodium; Hepatocellular carcinoma; Liver; Magnetic resonance imaging

Mesh:

Substances:

Year:  2021        PMID: 34545444     DOI: 10.1007/s00330-021-08267-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  25 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 2.  LI-RADS Version 2018 Ancillary Features at MRI.

Authors:  Milena Cerny; Victoria Chernyak; Damien Olivié; Jean-Sébastien Billiard; Jessica Murphy-Lavallée; Ania Z Kielar; Khaled M Elsayes; Laurence Bourque; Jonathan C Hooker; Claude B Sirlin; An Tang
Journal:  Radiographics       Date:  2018-10-05       Impact factor: 5.333

3.  Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography.

Authors:  Ijin Joo; Jeong Min Lee; Dong Ho Lee; Su Joa Ahn; Eun Sun Lee; Joon Koo Han
Journal:  J Magn Reson Imaging       Date:  2016-07-30       Impact factor: 4.813

4.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

5.  Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.

Authors:  Anita Paisant; Valérie Vilgrain; Jérémie Riou; Frédéric Oberti; Olivier Sutter; Valérie Laurent; Agnès Rodes; Boris Guiu; Christophe Cassinotto; Hervé Trillaud; Ivan Bricault; Sophie Michalak; Onorina Bruno; Maxime Ronot; Christophe Aubé
Journal:  J Hepatol       Date:  2019-12-21       Impact factor: 25.083

6.  Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.

Authors:  Claudia Khouri Chalouhi; Federica Vernuccio; Francesca Rini; Piergiorgio Duca; Bruno Tuscano; Giuseppe Brancatelli; Angelo Vanzulli
Journal:  Eur Radiol       Date:  2018-12-13       Impact factor: 5.315

7.  Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.

Authors:  Ji Hye Min; Jong Man Kim; Young Kon Kim; Tae Wook Kang; Soon Jin Lee; Gyu Seong Choi; Seo-Youn Choi; Soohyun Ahn
Journal:  Hepatology       Date:  2018-11-12       Impact factor: 17.425

Review 8.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

9.  Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria.

Authors:  Sang Hyun Choi; Jae Ho Byun; So Yeon Kim; So Jung Lee; Hyung Jin Won; Yong Moon Shin; Pyo Nyun Kim
Journal:  Invest Radiol       Date:  2016-08       Impact factor: 6.016

10.  LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features.

Authors:  Milena Cerny; Catherine Bergeron; Jean-Sébastien Billiard; Jessica Murphy-Lavallée; Damien Olivié; Joshua Bérubé; Boyan Fan; Hélène Castel; Simon Turcotte; Pierre Perreault; Miguel Chagnon; An Tang
Journal:  Radiology       Date:  2018-04-10       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.